Biotech & Life Sciences

All 22 Biotech & Life Sciences posts we have indexed from venture capital blogs and newsletters, plus the highest-scoring pieces of the past year and the people who write about it most.

Best of the past year
  • 2026: The State of AI in Healthcare Menlo VC · 16 Nov 2026

    Healthcare AI spending reached $3.7B in 2026 (2.5x growth), with pharma deploying at scale (+23x to $700M), incumbents winning back scribing, and clinical applications near patients emerging as the fastest-growing segment despite lengthening sales cycles.

  • AI is reshaping drug discovery economics by improving success rates and reducing development time and cost, potentially enabling pharma companies to earn "valuation credit" like software businesses and spawning a wave of AI-native biotech startups building discovery platforms or their own therapeutics.

  • Analysis of 179 preclinical biotech financings (2024–mid-2026) identifies four critical dimensions—CEO experience, lead investor strength, technology origin, and translational stage—that determine funding success. Companies strong in three or four dimensions raise 5–25x more capital at similar valuations, establishing a clear 'Trifecta+' funding archetype.

  • Investing at the Intersections Jeff Morris Jr. · 1 Nov 2026

    Venture capital's "edges" are converging: founders can now build simultaneously across bio, robotics, defense, manufacturing, and AI because foundational tools (models, simulation, robotics) have matured enough. These "intersection companies"—like Warhound (bio×AI×defense) and Warp (robotics×AI×biology)—attract multidisciplinary teams and unlock multi-product trajectories (SpaceX/Starlink precedent).

  • Optogenetics—the 2026 Nobel Prize-winning technique for controlling neurons with light—emerged through a nonlinear 55-year discovery chain spanning microbiology, structural biology, algae research, and neuroscience, illustrating how transformative scientific advances arise from distributed contributions across disconnected fields.

  • AI-driven molecular design is closing the loop between computational predictions and wet lab validation, but the bottleneck isn't automation of equipment—it's reliably interpreting experimental results to guide the next design iteration.

  • Clinical AI is shifting from administrative tasks to diagnosis and treatment decisions, driven by consumer demand and physician shortages. Success requires navigating regulatory complexity, reimbursement uncertainty, and the autonomy curve—not just raw model performance.

  • Science's Observability Problem Annelies Gamble · 1 Sept 2026

    Scientists' lab protocols contain thousands of undocumented decisions that create unexplained variation in results, hindering drug development and manufacturing scale-up. Transfyr is building observability infrastructure to capture what actually happens in experiments, not just what protocols say should happen.

Who writes about Biotech & Life Sciences

Alumni Ventures (10) · Not Boring (9) · Vickram Pradhan (3) · Radical VC (3) · Annelies Gamble (3) · A16Z (3) · yCombinator (2) · Guru Chahal (2) · Making Connections by Jax (1) · Teddy Blank (1)

Recent
Other topics
AI (Horizontal)AI InfrastructureEnterprise SoftwareDeveloper ToolsData & AnalyticsCybersecurityFintechInsuranceBanking & Capital MarketsCrypto & Web3HealthcareConsumerAll topics